Gene | Score gda | Association Type | Type | Original DB | Sentence supporting the association | PMID | PMID Year | ||||
---|---|---|---|---|---|---|---|---|---|---|---|
|
0.070 | Biomarker | phenotype | BEFREE | Immunoexpression of p53 and COX-2 in basal cell carcinoma. | 30845292 | 2018 | ||||
|
0.070 | Biomarker | phenotype | BEFREE | The fibrosing BCC subtype was associated with a higher degree of inflammation (p < 0.001) and revealed a higher COX-2 immunoreactivity than nodular BCC (p = 0.012). | 29775390 | 2018 | ||||
|
0.070 | AlteredExpression | phenotype | BEFREE | BCC and SCC intra-group analysis showed lower COX-2 activity in C-allele carriers versus non-carriers (p < 0.001 and p < 0.0001, respectively). | 22159575 | 2012 | ||||
|
0.070 | Biomarker | phenotype | BEFREE | Genetic deletion of COX-1 or COX-2 resulted in a robust decrease in BCC burden in patch heterozygote mice. | 20051366 | 2010 | ||||
|
0.070 | AlteredExpression | phenotype | BEFREE | While it cannot be ruled out that the present findings are due to chance, the results indicate that high COX-2 expression may increase risk of BCC while NSAID use may be protective. | 17307204 | 2007 | ||||
|
0.070 | GeneticVariation | phenotype | BEFREE | COX-2 common variants -765G-->C and -1195A-->G appear to be associated with risk of NMSC, although in different ways in the SCC and BCC subgroups, indicating that environmental and genetic risk factors may play different roles in the outcome leading to these two phenotypes. | 17578436 | 2007 | ||||
|
0.070 | AlteredExpression | phenotype | BEFREE | COX-2 was not detected in MCF-7 cells, but its expression in RMTCs was inhibited by SA treatment, which also significantly reduced BCC growth, but failed to cause cell death by necrosis or apoptosis. | 16596229 | 2006 |